Syntekabio Signs MOU with Gradient Bioconvergence for New Targeted Cancer Drug Development

AI new drug development specialist Syntekabio announced on the 22nd that it signed a memorandum of understanding (MOU) on the 19th with organoid specialist Gradient BioConvergence to establish an organoid-based AI new drug development platform and develop new target anticancer drugs.

Under this agreement, Gradient BioConvergence’s patient-derived organoid (PDO)-based drug responsiveness evaluation platform and Syntekabio’s AI new drug candidate discovery platform ‘DeepMatcher®’ will be utilized to build an organoid-based new drug candidate discovery service. They also plan to collaborate for innovative new drug development.

In addition, personalized neoantigens discovered through Syntekabio’s cancer neoantigen prediction AI platform ‘NEO-ARS®’ will be validated for efficacy using cancer patient-derived organoids from Gradient BioConvergence, and joint research for anticancer vaccine development will be promoted.

Gradient BioConvergence is strengthening joint research related to drug resistance and therapeutic efficacy evaluation by establishing a global-level PDO banking system. They are also developing anticancer drugs using their own PDO target discovery AI platform.

Syntekabio provides new drug candidate discovery and neoantigen prediction services through its proprietary DeepMatcher and NEO-ARS platforms. Recently, they launched the STB LaunchPad service based on a database of effective substances derived at various stages. Domestic and international pharmaceutical and bio companies and researchers can lower the entry barrier to AI new drug development and expand their service options through the STB LaunchPad. The company is actively conducting sales and marketing activities highlighting these advantages.

Syntekabio can secure high-quality efficacy data necessary for new drug development by utilizing Gradient BioConvergence’s PDO-based efficacy validation system. Gradient BioConvergence can expand its business area by leveraging Syntekabio’s various AI platforms and effective substance databases on its own AI platform. Both companies expect this to create business synergy.

Lee Jin-geun, CEO of Gradient BioConvergence, said, “We expect that the collaboration between Gradient BioConvergence, which has strengths in target discovery and drug efficacy evaluation, and Syntekabio, a leader in new drug candidate discovery, will increase the speed and success rate of new drug development,” adding, “In the future, both companies will do their best not only to develop new drug candidate discovery services but also to develop new target anticancer drugs.”

Cho Hye-kyung, Chief Operating Officer of Syntekabio, stated, “We expect to conduct meaningful joint research in new drug development by combining the technologies possessed by both companies,” and added, “In particular, by validating the efficacy of cancer neoantigens discovered by our NEO-ARS through organoid-based AI technology, we hope to increase the efficiency of new target anticancer drug development.”